SERPING1 and atypical hemolytic-uremic syndrome: The availability of effective C inhibitors for the classical pathway (C1-INH) and for the terminal pathway (eculizumab, anti-C5) provides new opportunities to treat life-threatening diseases like HAE, PNH, and aHUS.